Stock Analysts’ Upgrades for November, 7th (CTLT, GMLP, GMRE, NBL, NEWR, NTR, NTRS, ONCE, OXY, PGR)

Stock Analysts’ upgrades for Wednesday, November 7th:

Catalent (NYSE:CTLT) was upgraded by analysts at First Analysis from a neutral rating to an outperform rating. They currently have $43.00 target price on the stock, down from their previous target price of $47.00.

Golar LNG Partners (NASDAQ:GMLP) was upgraded by analysts at DNB Markets from a sell rating to a hold rating.

Global Medical REIT (NYSE:GMRE) was upgraded by analysts at Boenning Scattergood to a buy rating. Boenning Scattergood currently has $11.00 target price on the stock.

Noble Energy (NYSE:NBL) was upgraded by analysts at Tudor Pickering from a hold rating to a buy rating.

Noble Energy (NYSE:NBL) was upgraded by analysts at Raymond James from a market perform rating to an outperform rating.

New Relic (NYSE:NEWR) was upgraded by analysts at First Analysis from an outperform rating to a strong-buy rating. First Analysis currently has $116.00 price target on the stock, up from their previous price target of $114.00.

Nutrien (NYSE:NTR) was upgraded by analysts at TD Securities from a hold rating to a buy rating. They noted that the move was a valuation call. The analysts noted that the move was a valuation call.

Northern Trust (NASDAQ:NTRS) was upgraded by analysts at Wells Fargo & Co from a market perform rating to an outperform rating. The firm currently has $126.00 target price on the stock.

Spark Therapeutics (NASDAQ:ONCE) was upgraded by analysts at Wedbush from an underperform rating to a neutral rating. They noted that the move was a valuation call. The analysts noted that the move was a valuation call.

Spark Therapeutics (NASDAQ:ONCE) was upgraded by analysts at B. Riley from a neutral rating to a buy rating. The firm currently has $71.00 price target on the stock, up from their previous price target of $68.00.

Occidental Petroleum (NYSE:OXY) was upgraded by analysts at Evercore ISI to an outperform rating.

Progressive (NYSE:PGR) was upgraded by analysts at Morgan Stanley from an equal weight rating to a buy rating. The firm currently has $84.00 price target on the stock.

QEP Resources (NYSE:QEP) was upgraded by analysts at Tudor Pickering from a hold rating to a buy rating.

Ribbon Communications (NASDAQ:RBBN) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. They currently have $7.75 target price on the stock. According to Zacks, “Sonus Networks, Inc. is a leading provider of voice infrastructure products for the new public network. Sonus’ solutions enable service providers to deploy an integrated network capable of carrying both voice and data traffic, and to deliver a range of innovative, new services. The Sonus Open Services Architecture and award-winning Packet Telephony suite cut the time-to-market for competitive new service products, allowing carriers and third-party developers to expand marketshare and build important new revenue streams.(Press Release) “

REDHILL BIOPHAR/S (NASDAQ:RDHL) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. They currently have $9.25 price target on the stock. According to Zacks, “Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn’s disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103). “

Recro Pharma (NASDAQ:REPH) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. Zacks Investment Research currently has $8.25 price target on the stock. According to Zacks, “Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania. “

Replimune Group (NASDAQ:REPL) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company’s product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United States. “

Rev Group (NYSE:REVG) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “REV Group, Inc. designs, manufactures and distributes specialty vehicles, and related aftermarket parts and services. Its operating segment includes Fire & Emergency, Commercial and Recreation. Fire & Emergency segment provides ambulances, fire apparatus, school buses, mobility vans and municipal transit buses. Commercial segment provides industrial and commercial services through terminal trucks, cut-away buses and street sweepers. Recreation segment provides consumer leisure through recreational vehicles and luxury buses. REV Group, Inc. is headquartered in Milwaukee, WI. “

Regenxbio (NASDAQ:RGNX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $78.00 price target on the stock. According to Zacks, “REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland. “

Rigel Pharmaceuticals (NASDAQ:RIGL) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $3.25 target price on the stock. According to Zacks, “Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company’s pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel’s productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer. “

Regional Management (NYSE:RM) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Regional Management Corp. is a diversified specialty consumer finance company engaged in providing loan products primarily to customers with limited access to consumer credit from banks, thrifts, credit card companies and other traditional lenders. It offers Small Installment Loans, Large Installment Loans, Automobile Purchase Loans, Furniture and Appliance Purchase Loans and Insurance Products. The Company has operations primarily in South Carolina, Texas, North Carolina, Tennessee and Alabama. Regional Management Corp. is headquartered in Greenville, South Carolina. “

Rubius Therapeutics (NASDAQ:RUBY) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Rubius Therapeutics, Inc. is a bio-technology company. It develops cellular therapies for the treatment of auto-immune, metabolic and other diseases. Rubius Therapeutics, Inc. is based in Cambridge, United States. “

Revance Therapeutics (NASDAQ:RVNC) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $28.00 price target on the stock. According to Zacks, “Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance’s science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance’s initial focus is on developing daxibotulinumtoxinA, the company’s highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company’s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. “

Riverview Bancorp (NASDAQ:RVSB) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $9.50 price target on the stock. According to Zacks, “Riverview Bancorp, Inc. is a holding company for Riverview Savings Bank. The bank is a community oriented financial institution offering traditional financial services to the residents of its primary market area. The bank is engaged in the business of attracting deposits from the public and using such funds to originate fixed-rate mortgage loans and adjustable rate mortgage loans secured by one- to- four family residential real estate located in its primary market area. The bank is an active originator of residential construction loans and consumer loans. “

Target (NYSE:TGT) was upgraded by analysts at Cowen Inc from a market perform rating to an outperform rating.

USA Compression Partners (NYSE:USAC) was upgraded by analysts at Royal Bank of Canada from a sector perform rating to an outperform rating.

Western Gas Partners (NYSE:WES) was upgraded by analysts at Bank of America Corp from a neutral rating to a buy rating. They currently have $51.00 target price on the stock.

Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply